CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Pfizer Publishes Q3 2026 Earnings Call Transcript

By Public Technologies
  • Pfizer raised full-year 2026 revenue guidance to $62 billion-$64 billion, up $1.5 billion at the midpoint.
  • Adjusted diluted EPS guidance increased to $2.95-$3.05, incorporating a $0.10-per-share charge from the Innovent transaction.
  • Third-quarter revenue reached $16.6 billion; adjusted diluted EPS totaled $0.87.
  • Management expects nearly $7.2 billion in net savings by year-end, with another $2.5 billion targeted for 2027-2029.
  • The November 3 earnings call included CEO Albert Bourla, CFO Cecile Guegan and R&D chief Chris Boshoff.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk